Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 323

1.

Clinical Factors Associated with Acute Exacerbations of Chronic Rhinosinusitis.

Kwah JH, Somani SN, Stevens WW, Kern RC, Smith SS, Welch KC, Conley DB, Tan BK, Grammer LC, Yang A, Schleimer RP, Peters AT.

J Allergy Clin Immunol. 2020 Jan 28. pii: S0091-6749(20)30112-3. doi: 10.1016/j.jaci.2020.01.023. [Epub ahead of print]

PMID:
32004523
2.

Radiologic sinus inflammation and symptoms of chronic rhinosinusitis in a population-based sample.

Hirsch AG, Nordberg C, Bandeen-Roche K, Tan BK, Schleimer RP, Kern RC, Sundaresan A, Pinto JM, Kennedy TL, Greene JS, Kuiper JR, Schwartz BS.

Allergy. 2019 Nov 11. doi: 10.1111/all.14106. [Epub ahead of print]

PMID:
31713250
3.

Role of RANK-L as a potential inducer of ILC2-mediated type 2 inflammation in chronic rhinosinusitis with nasal polyps.

Ogasawara N, Poposki JA, Klingler AI, Tan BK, Hulse KE, Stevens WW, Peters AT, Grammer LC, Welch KC, Smith SS, Conley DB, Raviv JR, Soroosh P, Takano KI, Himi T, Kern RC, Schleimer RP, Kato A.

Mucosal Immunol. 2020 Jan;13(1):86-95. doi: 10.1038/s41385-019-0215-8. Epub 2019 Oct 22.

PMID:
31641233
4.

Prevalence and characterization of chronic rhinosinusitis in patients with non-cystic fibrosis bronchiectasis at a tertiary care center in the United States.

Somani SN, Kwah JH, Yeh C, Conley DB, Grammer LC 3rd, Kern RC, Prickett M, Schleimer RP, Smith SS, Stevens WW, Tan BK, Welch KC, Peters AT.

Int Forum Allergy Rhinol. 2019 Dec;9(12):1424-1429. doi: 10.1002/alr.22436. Epub 2019 Oct 7.

PMID:
31589811
5.

Increased thrombin-activatable fibrinolysis inhibitor levels in patients with chronic rhinosinusitis with nasal polyps.

Imoto Y, Kato A, Takabayashi T, Stevens W, Norton JE, Suh LA, Carter RG, Weibman AR, Hulse KE, Harris KE, Peters AT, Grammer LC, Tan BK, Welch K, Shintani-Smith S, Conley DB, Kern RC, Fujieda S, Schleimer RP.

J Allergy Clin Immunol. 2019 Dec;144(6):1566-1574.e6. doi: 10.1016/j.jaci.2019.08.040. Epub 2019 Sep 25.

PMID:
31562871
6.

TNF induces production of type 2 cytokines in human group 2 innate lymphoid cells.

Ogasawara N, Poposki JA, Klingler AI, Tan BK, Hulse KE, Stevens WW, Peters AT, Grammer LC, Welch KC, Smith SS, Conley DB, Takano KI, Himi T, Kern RC, Schleimer RP, Kato A.

J Allergy Clin Immunol. 2020 Jan;145(1):437-440.e8. doi: 10.1016/j.jaci.2019.09.001. Epub 2019 Sep 14. No abstract available.

PMID:
31526804
7.

Workplace Indirect Cost Impacts of Nasal and Sinus Symptoms and Related Conditions.

Kuiper JR, Hirsch AG, Bandeen-Roche K, Sundaresan AS, Tan BK, Kern RC, Schleimer RP, Schwartz BS.

J Occup Environ Med. 2019 Aug;61(8):e333-e339. doi: 10.1097/JOM.0000000000001636.

8.

Associations Between Inflammatory Endotypes and Clinical Presentations in Chronic Rhinosinusitis.

Stevens WW, Peters AT, Tan BK, Klingler AI, Poposki JA, Hulse KE, Grammer LC, Welch KC, Smith SS, Conley DB, Kern RC, Schleimer RP, Kato A.

J Allergy Clin Immunol Pract. 2019 Nov - Dec;7(8):2812-2820.e3. doi: 10.1016/j.jaip.2019.05.009. Epub 2019 May 22.

PMID:
31128376
9.

Identification of whole blood mRNA and microRNA biomarkers of tissue damage and immune function resulting from amphetamine exposure or heat stroke in adult male rats.

Camacho L, Silva CS, Hanig JP, Schleimer RP, George NI, Bowyer JF.

PLoS One. 2019 Feb 19;14(2):e0210273. doi: 10.1371/journal.pone.0210273. eCollection 2019.

10.

Prevalence and Severity of Food Allergies Among US Adults.

Gupta RS, Warren CM, Smith BM, Jiang J, Blumenstock JA, Davis MM, Schleimer RP, Nadeau KC.

JAMA Netw Open. 2019 Jan 4;2(1):e185630. doi: 10.1001/jamanetworkopen.2018.5630.

11.

Increased expression of L-plastin in nasal polyp of patients with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease.

Takabayashi T, Tanaka Y, Susuki D, Yoshida K, Tomita K, Sakashita M, Imoto Y, Kato Y, Narita N, Nakayama T, Haruna S, Schleimer RP, Fujieda S.

Allergy. 2019 Jul;74(7):1307-1316. doi: 10.1111/all.13677. Epub 2018 Dec 17.

PMID:
30479022
12.

Clinical Characteristics of Patients with Chronic Rhinosinusitis without Nasal Polyps in an AcademicĀ Setting.

Benjamin MR, Stevens WW, Li N, Bose S, Grammer LC, Kern RC, Tan BK, Conley DB, Smith SS, Welch KC, Schleimer RP, Peters AT.

J Allergy Clin Immunol Pract. 2019 Mar;7(3):1010-1016. doi: 10.1016/j.jaip.2018.10.014. Epub 2018 Oct 25.

PMID:
30368005
13.

Pathophysiologic mechanisms of chronic rhinosinusitis and their roles in emerging disease endotypes.

Cao PP, Wang ZC, Schleimer RP, Liu Z.

Ann Allergy Asthma Immunol. 2019 Jan;122(1):33-40. doi: 10.1016/j.anai.2018.10.014. Epub 2018 Oct 13. Review.

14.

Association of nasal microbiome and asthma control in patients with chronic rhinosinusitis.

Yang HJ, LoSavio PS, Engen PA, Naqib A, Mehta A, Kota R, Khan RJ, Tobin MC, Green SJ, Schleimer RP, Keshavarzian A, Batra PS, Mahdavinia M.

Clin Exp Allergy. 2018 Dec;48(12):1744-1747. doi: 10.1111/cea.13255. Epub 2018 Sep 24. No abstract available.

15.

Epithelial activators of type 2 inflammation: Elevation of thymic stromal lymphopoietin, but not IL-25 or IL-33, in chronic rhinosinusitis with nasal polyps in Chicago, Illinois.

Ogasawara N, Klingler AI, Tan BK, Poposki JA, Hulse KE, Stevens WW, Peters AT, Grammer LC, Welch KC, Smith SS, Conley DB, Kern RC, Schleimer RP, Kato A.

Allergy. 2018 Nov;73(11):2251-2254. doi: 10.1111/all.13552. Epub 2018 Jul 26. No abstract available.

16.

Pathogenic and protective roles of B cells and antibodies in patients with chronic rhinosinusitis.

Tan BK, Peters AT, Schleimer RP, Hulse KE.

J Allergy Clin Immunol. 2018 May;141(5):1553-1560. doi: 10.1016/j.jaci.2018.03.002. Review.

17.

Longitudinal evaluation of clustering of chronic sinonasal and related symptoms using exploratory factor analysis.

Cole M, Bandeen-Roche K, Hirsch AG, Kuiper JR, Sundaresan AS, Tan BK, Schleimer RP, Kern RC, Schwartz BS.

Allergy. 2018 Aug;73(8):1715-1723. doi: 10.1111/all.13470. Epub 2018 May 21.

18.

Genome-wide association study of maternal genetic effects and parent-of-origin effects on food allergy.

Liu X, Hong X, Tsai HJ, Mestan KK, Shi M, Kefi A, Hao K, Chen Q, Wang G, Caruso D, Geng H, Gao Y, He J, Kumar R, Wang H, Yu Y, Bartell T, Tan XD, Schleimer RP, Weeks DE, Pongracic JA, Wang X.

Medicine (Baltimore). 2018 Mar;97(9):e0043. doi: 10.1097/MD.0000000000010043.

19.

Mast cell-derived plasminogen activator inhibitor type 1 promotes airway inflammation and remodeling in a murine model of asthma.

Jo A, Lee SH, Kim DY, Hong SJ, Teng MN, Kolliputi N, Lockey RF, Schleimer RP, Cho SH.

J Allergy Clin Immunol. 2018 Jul;142(1):294-297.e5. doi: 10.1016/j.jaci.2018.01.040. Epub 2018 Mar 2. No abstract available. Erratum in: J Allergy Clin Immunol. 2018 Nov;142(5):1678.

20.

The nasal microbiome in patients with chronic rhinosinusitis: Analyzing the effects of atopy and bacterial functional pathways in 111 patients.

Mahdavinia M, Engen PA, LoSavio PS, Naqib A, Khan RJ, Tobin MC, Mehta A, Kota R, Preite NZ, Codispoti CD, Tajudeen BA, Schleimer RP, Green SJ, Keshavarzian A, Batra PS.

J Allergy Clin Immunol. 2018 Jul;142(1):287-290.e4. doi: 10.1016/j.jaci.2018.01.033. Epub 2018 Feb 13. No abstract available.

21.

Short-chain fatty acids induce tissue plasminogen activator in airway epithelial cells via GPR41&43.

Imoto Y, Kato A, Takabayashi T, Sakashita M, Norton JE, Suh LA, Carter RG, Weibman AR, Hulse KE, Stevens W, Harris KE, Peters AT, Grammer LC, Tan BK, Welch K, Conley DB, Kern RC, Fujieda S, Schleimer RP.

Clin Exp Allergy. 2018 May;48(5):544-554. doi: 10.1111/cea.13119. Epub 2018 Mar 24.

22.

Prevalence, severity, and risk factors for acute exacerbations of nasal and sinus symptoms by chronic rhinosinusitis status.

Kuiper JR, Hirsch AG, Bandeen-Roche K, Sundaresan AS, Tan BK, Schleimer RP, Kern RC, Stewart WF, Schwartz BS.

Allergy. 2018 Jun;73(6):1244-1253. doi: 10.1111/all.13409. Epub 2018 Feb 7.

23.

Asthma onset pattern and patient outcomes in a chronic rhinosinusitis population.

John Staniorski C, Price CPE, Weibman AR, Welch KC, Conley DB, Shintani-Smith S, Stevens WW, Peters AT, Grammer L, Lidder AK, Schleimer RP, Kern RC, Tan BK.

Int Forum Allergy Rhinol. 2018 Apr;8(4):495-503. doi: 10.1002/alr.22064. Epub 2018 Jan 5.

24.

Longitudinal Evaluation of Chronic Rhinosinusitis Symptoms in a Population-Based Sample.

Sundaresan AS, Hirsch AG, Young AJ, Pollak J, Tan BK, Schleimer RP, Kern RC, Kennedy TL, Greene JS, Stewart WF, Bandeen-Roche K, Schwartz BS.

J Allergy Clin Immunol Pract. 2018 Jul - Aug;6(4):1327-1335.e3. doi: 10.1016/j.jaip.2017.10.012. Epub 2017 Nov 10.

25.

Reply.

Stevens WW, Suh L, Peters AT, Schleimer RP.

J Allergy Clin Immunol Pract. 2017 Nov - Dec;5(6):1808-1809. doi: 10.1016/j.jaip.2017.08.018. No abstract available.

26.

IL-10, TGF-Ī², and glucocorticoid prevent the production of type 2 cytokines in human group 2 innate lymphoid cells.

Ogasawara N, Poposki JA, Klingler AI, Tan BK, Weibman AR, Hulse KE, Stevens WW, Peters AT, Grammer LC, Schleimer RP, Welch KC, Smith SS, Conley DB, Raviv JR, Soroosh P, Akbari O, Himi T, Kern RC, Kato A.

J Allergy Clin Immunol. 2018 Mar;141(3):1147-1151.e8. doi: 10.1016/j.jaci.2017.09.025. Epub 2017 Oct 23. No abstract available.

27.

A prospective analysis evaluating tissue biopsy location and its clinical relevance in chronic rhinosinusitis with nasal polyps.

Weibman AR, Huang JH, Stevens WW, Suh LA, Price CPE, Lidder AK, Conley DB, Welch KC, Shintani-Smith S, Peters AT, Grammer LC, Kato A, Kern RC, Schleimer RP, Tan BK.

Int Forum Allergy Rhinol. 2017 Nov;7(11):1058-1064. doi: 10.1002/alr.22005. Epub 2017 Sep 1.

28.

The barrier hypothesis and Oncostatin M: Restoration of epithelial barrier function as a novel therapeutic strategy for the treatment of type 2 inflammatory disease.

Pothoven KL, Schleimer RP.

Tissue Barriers. 2017 Jul 3;5(3):e1341367. doi: 10.1080/21688370.2017.1341367. Epub 2017 Jun 13. Review.

29.

Evidence for altered levels of IgD in the nasal airway mucosa of patients with chronic rhinosinusitis.

Min JY, Nayak JV, Hulse KE, Stevens WW, Raju PA, Huang JH, Suh LA, Van Roey GA, Norton JE, Carter RG, Price CPE, Weibman AR, Rashan AR, Ghosn EE, Patel ZM, Homma T, Conley DB, Welch KC, Shintani-Smith S, Peters AT, Grammer LC 3rd, Harris KE, Kato A, Hwang PH, Kern RC, Herzenberg LA, Schleimer RP, Tan BK.

J Allergy Clin Immunol. 2017 Dec;140(6):1562-1571.e5. doi: 10.1016/j.jaci.2017.05.032. Epub 2017 Jun 16.

30.

Etiology of epithelial barrier dysfunction in patients with type 2 inflammatory diseases.

Schleimer RP, Berdnikovs S.

J Allergy Clin Immunol. 2017 Jun;139(6):1752-1761. doi: 10.1016/j.jaci.2017.04.010. Review.

31.

Regulatory T-cell populations in children are affected by age and food allergy diagnosis.

Prince BT, Devonshire AL, Erickson KA, Bergerson J, Fuleihan D, Szychlinski C, Schleimer RP, Bryce PJ, Singh AM.

J Allergy Clin Immunol. 2017 Oct;140(4):1194-1196.e16. doi: 10.1016/j.jaci.2017.04.039. Epub 2017 May 23. No abstract available.

32.

Granulocyte colony-stimulating factor blockade enables dexamethasone to inhibit lipopolysaccharide-induced murine lung neutrophils.

Banuelos J, Cao Y, Shin SC, Bochner BS, Avila P, Li S, Jiang X, Lingen MW, Schleimer RP, Lu NZ.

PLoS One. 2017 May 19;12(5):e0177884. doi: 10.1371/journal.pone.0177884. eCollection 2017.

33.

Group 2 innate lymphoid cells are elevated and activated in chronic rhinosinusitis with nasal polyps.

Poposki JA, Klingler AI, Tan BK, Soroosh P, Banie H, Lewis G, Hulse KE, Stevens WW, Peters AT, Grammer LC, Schleimer RP, Welch KC, Smith SS, Conley DB, Raviv JR, Karras JG, Akbari O, Kern RC, Kato A.

Immun Inflamm Dis. 2017 Sep;5(3):233-243. doi: 10.1002/iid3.161. Epub 2017 Apr 19.

34.

Risk of obstructive sleep apnea in African American patients with chronic rhinosinusitis.

Hui JW, Ong J, Herdegen JJ, Kim H, Codispoti CD, Kalantari V, Tobin MC, Schleimer RP, Batra PS, LoSavio PS, Mahdavinia M.

Ann Allergy Asthma Immunol. 2017 Jun;118(6):685-688.e1. doi: 10.1016/j.anai.2017.03.009. Epub 2017 Apr 27.

35.

Potential Involvement of the Epidermal Growth Factor Receptor Ligand Epiregulin and Matrix Metalloproteinase-1 in Pathogenesis of Chronic Rhinosinusitis.

Homma T, Kato A, Sakashita M, Takabayashi T, Norton JE, Suh LA, Carter RG, Harris KE, Peters AT, Grammer LC, Min JY, Shintani-Smith S, Tan BK, Welch K, Conley DB, Kern RC, Schleimer RP.

Am J Respir Cell Mol Biol. 2017 Sep;57(3):334-345. doi: 10.1165/rcmb.2016-0325OC.

36.

Superior turbinate eosinophilia correlates with olfactory deficit in chronic rhinosinusitis patients.

Lavin J, Min JY, Lidder AK, Huang JH, Kato A, Lam K, Meen E, Chmiel JS, Norton J, Suh L, Mahdavinia M, Hulse KE, Conley DB, Chandra RK, Shintani-Smith S, Kern RC, Schleimer RP, Tan BK.

Laryngoscope. 2017 Oct;127(10):2210-2218. doi: 10.1002/lary.26555. Epub 2017 Mar 21.

37.

Clinical Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin-Exacerbated Respiratory Disease.

Stevens WW, Peters AT, Hirsch AG, Nordberg CM, Schwartz BS, Mercer DG, Mahdavinia M, Grammer LC, Hulse KE, Kern RC, Avila P, Schleimer RP.

J Allergy Clin Immunol Pract. 2017 Jul - Aug;5(4):1061-1070.e3. doi: 10.1016/j.jaip.2016.12.027. Epub 2017 Mar 9.

38.

Sleep disruption in chronic rhinosinusitis.

Mahdavinia M, Schleimer RP, Keshavarzian A.

Expert Rev Anti Infect Ther. 2017 May;15(5):457-465. doi: 10.1080/14787210.2017.1294063. Epub 2017 Feb 17. Review.

39.

Microparticles in nasal lavage fluids in chronic rhinosinusitis: Potential biomarkers for diagnosis of aspirin-exacerbated respiratory disease.

Takahashi T, Kato A, Berdnikovs S, Stevens WW, Suh LA, Norton JE, Carter RG, Harris KE, Peters AT, Hulse KE, Grammer LC, Welch KC, Shintani-Smith S, Tan BK, Conley DB, Kern RC, Bochner BS, Schleimer RP.

J Allergy Clin Immunol. 2017 Sep;140(3):720-729. doi: 10.1016/j.jaci.2017.01.022. Epub 2017 Feb 24.

40.

Evaluating metrics of responsiveness using patient-reported outcome measures in chronic rhinosinusitis.

Lidder AK, Detwiller KY, Price CP, Kern RC, Conley DB, Shintani-Smith S, Welch KC, Chandra RK, Peters AT, Grammer LC 3rd, Man LX, Schleimer RP, Tan BK.

Int Forum Allergy Rhinol. 2017 Feb;7(2):128-134. doi: 10.1002/alr.21866. Epub 2016 Nov 7.

41.

The Clinical Significance of Specific Antibody Deficiency (SAD) Severity in Chronic Rhinosinusitis (CRS).

Keswani A, Dunn NM, Manzur A, Kashani S, Bossuyt X, Grammer LC, Conley DB, Tan BK, Kern RC, Schleimer RP, Peters AT.

J Allergy Clin Immunol Pract. 2017 Jul - Aug;5(4):1105-1111. doi: 10.1016/j.jaip.2016.11.033. Epub 2017 Jan 26.

42.

Chronic airway inflammation provides a unique environment for B cell activation and antibody production.

Feldman S, Kasjanski R, Poposki J, Hernandez D, Chen JN, Norton JE, Suh L, Carter RG, Stevens WW, Peters AT, Kern RC, Conley DB, Tan BK, Shintani-Smith S, Welch KC, Grammer LC, Harris KE, Kato A, Schleimer RP, Hulse KE.

Clin Exp Allergy. 2017 Apr;47(4):457-466. doi: 10.1111/cea.12878. Epub 2017 Jan 26.

43.

Neutrophils are a major source of the epithelial barrier disrupting cytokine oncostatin M in patients with mucosal airways disease.

Pothoven KL, Norton JE, Suh LA, Carter RG, Harris KE, Biyasheva A, Welch K, Shintani-Smith S, Conley DB, Liu MC, Kato A, Avila PC, Hamid Q, Grammer LC 3rd, Peters AT, Kern RC, Tan BK, Schleimer RP.

J Allergy Clin Immunol. 2017 Jun;139(6):1966-1978.e9. doi: 10.1016/j.jaci.2016.10.039. Epub 2016 Dec 18.

44.

Classical complement pathway activation in the nasal tissue of patients with chronic rhinosinusitis.

Van Roey GA, Vanison CC, Wu J, Huang JH, Suh LA, Carter RG, Norton JE, Shintani-Smith S, Conley DB, Welch KC, Peters AT, Grammer LC, Harris KE, Hulse KE, Kato A, Stevens WW, Kern RC, Schleimer RP, Tan BK.

J Allergy Clin Immunol. 2017 Jul;140(1):89-100.e2. doi: 10.1016/j.jaci.2016.11.015. Epub 2016 Dec 12.

45.

Immunopathogenesis of Chronic Rhinosinusitis and Nasal Polyposis.

Schleimer RP.

Annu Rev Pathol. 2017 Jan 24;12:331-357. doi: 10.1146/annurev-pathol-052016-100401. Epub 2016 Dec 5. Review.

46.

Proprotein convertases generate a highly functional heterodimeric form of thymic stromal lymphopoietin in humans.

Poposki JA, Klingler AI, Stevens WW, Peters AT, Hulse KE, Grammer LC, Schleimer RP, Welch KC, Smith SS, Sidle DM, Conley DB, Tan BK, Kern RC, Kato A.

J Allergy Clin Immunol. 2017 May;139(5):1559-1567.e8. doi: 10.1016/j.jaci.2016.08.040. Epub 2016 Oct 12.

47.

Proton pump inhibitors decrease eotaxin-3/CCL26 expression in patients with chronic rhinosinusitis with nasal polyps: Possible role of the nongastric H,K-ATPase.

Min JY, Ocampo CJ, Stevens WW, Price CPE, Thompson CF, Homma T, Huang JH, Norton JE, Suh LA, Pothoven KL, Conley DB, Welch KC, Shintani-Smith S, Peters AT, Grammer LC 3rd, Harris KE, Hulse KE, Kato A, Modyanov NN, Kern RC, Schleimer RP, Tan BK.

J Allergy Clin Immunol. 2017 Jan;139(1):130-141.e11. doi: 10.1016/j.jaci.2016.07.020. Epub 2016 Oct 4.

48.

Aspirin-Exacerbated Respiratory Disease as an Endotype of Chronic Rhinosinusitis.

Stevens WW, Schleimer RP.

Immunol Allergy Clin North Am. 2016 Nov;36(4):669-680. doi: 10.1016/j.iac.2016.06.004. Epub 2016 Sep 13. Review.

49.

Heterogeneous inflammatory patterns in chronic rhinosinusitis without nasal polyps in Chicago, Illinois.

Tan BK, Klingler AI, Poposki JA, Stevens WW, Peters AT, Suh LA, Norton J, Carter RG, Hulse KE, Harris KE, Grammer LC, Schleimer RP, Welch KC, Smith SS, Conley DB, Kern RC, Kato A.

J Allergy Clin Immunol. 2017 Feb;139(2):699-703.e7. doi: 10.1016/j.jaci.2016.06.063. Epub 2016 Sep 14. No abstract available.

50.

Allergens stimulate store-operated calcium entry and cytokine production in airway epithelial cells.

Jairaman A, Maguire CH, Schleimer RP, Prakriya M.

Sci Rep. 2016 Sep 8;6:32311. doi: 10.1038/srep32311.

Supplemental Content

Loading ...
Support Center